Clinical-stage pharmaceutical firm Allarity Therapeutics and Detsamma Investments (trading as FivepHusion) are collaborating to develop Deflexifol, a novel anti-cancer drug formulation for the treatment of solid tumors, using Allarity's drug-specific companion diagnostics (DRP) technology to potentially select patients for clinical trials.
The partnership aims to advance the clinical development of Deflexifol, an optimized all-in-one formulation of the chemotherapeutic agent 5-fluorouracil (5FU) and leucovorin (LV). Allarity's DRP companion diagnostics will be used to identify patients likely to respond to Deflexifol in a Phase Ib/IIa study investigating the drug, in combination with oxaliplatin and bevacizumab for unresectable metastatic colorectal cancer.
The collaboration seeks to provide personalized cancer care by selecting patients who are most likely to benefit from the novel treatment. Following the study, FivepHusion will have the option to negotiate an exclusive license to use and commercialize the DRP-5FU CDx and other relevant DRP CDx in future trials and marketing efforts for Deflexifol.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.